Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma

Study Overview
=================
Brief Summary
-----------------
Glaucoma is the second leading cause of blindness among seniors in Canada. It is often associated with an elevated intraocular pressure (IOP), but its exact mechanism is still largely unknown. Some studies have shown a link between glaucoma and changes in the amount of oxygen in the veins of the eye. The study aims to compare the amount of oxygen in ocular veins among three different groups using a spectrophotometer. This instrument is linked to a camera and can measure the quantity of oxygen in the veins using different characteristics of the blood inside. The groups of the study are: patients without glaucoma, patients suspected of glaucoma and patients newly diagnosed with glaucoma. The drug the investigators are using, Travoprost 0.004%, will only be administered to the groups suspected or diagnosed with glaucoma. Travoprost 0.004% is already approved for use in Quebec and is part of standard care. Ten patients will be recruited into each group for a total of 30 patients in this study. All patients for the suspected or diagnosed groups will be recruited from the Jewish General Hospital. Subsequently all testing will be done at the École d'optométrie, Université de Montréal

Official Title
-----------------
Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma

Conditions
-----------------
Primary Open Angle Glaucoma

Intervention / Treatment
-----------------
* Drug: placebo
* Drug: travoprost


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: good systemic health irido-corneal angle open intraocular pressure more than 18 mmHg Exclusion Criteria: having cardiovascular problem Hypertension or diabetes under systemic medication for high blood pressure had an ocular surgery in the past

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: Normal control<br>Normal patient placebo | Drug: placebo<br>* Placebo<br>|
| Sham Comparator: Glaucoma suspect<br>Patients with elevated Intraocular pressure higher than 18 mmHg (placebo) | Drug: placebo<br>* Placebo<br>|
| Experimental: Newly diagnosed glaucoma<br>Treated with Travoprost (0.04%) | Drug: travoprost<br>* Travatan Z is administered to newly diagnosed glaucoma patient<br>* Other names: travatan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood Oxygenation | For each subject, all the measurements will be done during an 1 hour appointment. | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
primary open angle glaucoma, retinal oximetry